<DOC>
	<DOCNO>NCT02557750</DOCNO>
	<brief_summary>The aim study retrospectively investigate effect combine modality treatment pediatric hepatoblastoma factor affect prognosis accordance experience pediatric oncology department South Egypt Cancer Institute .</brief_summary>
	<brief_title>Combined Modality Therapy Hepatoblastoma : South Egypt Cancer Institute Experience</brief_title>
	<detailed_description>Background : Hepatoblastoma ( HB ) common malignant liver tumor child , incidence 0.7 1 per million child &lt; 15 year age . Till 1970s , surgery primary modality treatment HB . Unfortunately , 60 % patient present unresectable stage . Later , chemo- responsiveness tumor demonstrate led incorporation adjuvant chemotherapy cisplatinum doxorubicin treatment HB . International Society Pediatric Oncology ( SIOP ) pioneer concept neoadjuvant chemotherapy management HB . Patients &amp; Methods : In period 2002 January till 2016 January , retrieval &amp; analysis medical record pediatric patient hepatoblastoma make pediatric oncology department , South Egypt Cancer Institute represent large referral center Upper Egypt . After pathologic confirmation diagnosis , data categorize accord patient ' demographic , present feature , laboratory study , include tumor marker &amp; histologic subtype , radiographic evaluation , disease staging , treatment course give , subsequent treatment outcome .</detailed_description>
	<mesh_term>Hepatoblastoma</mesh_term>
	<criteria>Patients whose age less equal 18 year . Patients diagnose hepatoblastoma . Patients whose age 18 year .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Childhood Cancer</keyword>
	<keyword>Pediatric Oncology</keyword>
</DOC>